Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2015

01-03-2015 | Research Article

Downregulation of RIP140 in hepatocellular carcinoma promoted the growth and migration of the cancer cells

Authors: Dexiang Zhang, Yueqi Wang, Yuedi Dai, Jiwen Wang, Tao Suo, Hongtao Pan, Han Liu, Sheng Shen, Houbao Liu

Published in: Tumor Biology | Issue 3/2015

Login to get access

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies with a poor response to chemotherapy. It is very important to identify novel diagnosis biomarkers and therapeutic targets. RIP140, a regulator of estrogen receptor, recently has been found to be involved in the tumorigenesis. However, its function in the progression of HCC remains poorly understood. Here, we found that the expression of RIP140 was downregulated in the HCC tissues. Moreover, overexpression of RIP140 in HCC cells inhibited cell proliferation and migration, while downregulation of RIP140 promoted the tumorigenicity of HCC cells in vitro and in vivo. Mechanistically, RIP140 interacted with beta-catenin and negatively regulated beta-catenin/TCF signaling. Taken together, our study suggests the suppressive roles of RIP140 in the pathogenesis of HCC.
Literature
1.
2.
Dwyer JP, Hosking P, Lubel J. Multiple liver lesions in a patient with positive hepatitis C serology and elevated AFP: is it HCC? Gastroenterology. 2014;147:e12–3.CrossRefPubMed
3.
Cho JY, Paik YH, Sohn W, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014;63:1943–50.CrossRefPubMed
4.
Levi D, Tzakis A. HBV and HCC: comment on “Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a Western dual-center experience”. Arch Surg. 2009;144(10):913.CrossRefPubMed
5.
Enwonwu CO. The role of dietary aflatoxin in the genesis of hepatocellular cancer in developing countries. Lancet. 1984;2(8409):956–8.CrossRefPubMed
6.
Trevisani F, Cantarini MC, Labate AM, et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol. 2004;99(8):1470–6.CrossRefPubMed
7.
Park EK, Kim HJ, Kim CY, et al. A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. Ann Surg Treat Res. 2012;87(2):72–80.CrossRef
8.
Yamashita Y, Imai D, Bekki Y, et al. Surgical outcomes of anatomical resection for solitary recurrent hepatocellular carcinoma. Anticancer Res. 2012;34(8):4421–6.
9.
Wan HG, Xu H, Gu YM, Wang H, Xu W, Zu MH (2014) Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis. Clin Res Hepatol Gastroenterol.
10.
De Rienzo G, Bishop JA, Mao Y, et al. Disc1 regulates both beta-catenin-mediated and noncanonical Wnt signaling during vertebrate embryogenesis. Faseb J. 2012;25(12):4184–97.CrossRef
11.
Kolligs FT, Bommer G, Goke B. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion. 2002;66(3):131–44.CrossRefPubMed
12.
Cong F, Schweizer L, Varmus H. Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development. 2004;131(20):5103–15.CrossRefPubMed
13.
Li YJ, Wei ZM, Meng YX, Ji XR. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol. 2005;11(14):2117–23.CrossRefPubMedPubMedCentral
14.
Stemmer V, de Craene B, Berx G, Behrens J. Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene. 2008;27(37):5075–80.CrossRefPubMed
15.
Dahmani R, Just PA, Perret C. The Wnt/beta-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2009;35(11):709–13.CrossRef
16.
Cavard C, Colnot S, Audard V, et al. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol. 2008;4(5):647–60.CrossRefPubMed
17.
Li P, Cao Y, Li Y, Zhou L, Liu X, Geng M. Expression of Wnt-5a and beta-catenin in primary hepatocellular carcinoma. Int J Clin Exp Pathol. 2012;7(6):3190–5.
18.
Lin J, Ding L, Jin R, et al. Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140 kDa (RIP140) interact and cooperate in estrogen signaling. Int J Biochem Cell Biol. 2009;41(7):1613–8.CrossRefPubMed
19.
Cavailles V, Dauvois S, L'Horset F, et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. Embo J. 1995;14(15):3741–51.PubMedPubMedCentral
20.
Docquier A, Harmand PO, Fritsch S, Chanrion M, Darbon JM, Cavailles V. The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes. Clin Cancer Res. 2012;16(11):2959–70.CrossRef
21.
Zschiedrich I, Hardeland U, Krones-Herzig A, et al. Coactivator function of RIP140 for NFkappaB/RelA-dependent cytokine gene expression. Blood. 2008;112(2):264–76.CrossRefPubMed
22.
Heery DM, Hoare S, Hussain S, Parker MG, Sheppard H. Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J Biol Chem. 2001;276(9):6695–702.CrossRefPubMed
23.
Carascossa S, Gobinet J, Georget V, et al. Receptor-interacting protein 140 is a repressor of the androgen receptor activity. Mol Endocrinol. 2006;20(7):1506–18.CrossRefPubMedPubMedCentral
24.
25.
Rytinki MM, Palvimo JJ. SUMOylation modulates the transcription repressor function of RIP140. J Biol Chem. 2008;283(17):11586–95.CrossRefPubMed
26.
Ho PC, Gupta P, Tsui YC, Ha SG, Huq M, Wei LN. Modulation of lysine acetylation-stimulated repressive activity by Erk2-mediated phosphorylation of RIP140 in adipocyte differentiation. Cell Signal. 2008;20(10):1911–9.CrossRefPubMedPubMedCentral
27.
Heim KC, Gamsby JJ, Hever MP, et al. Retinoic acid mediates long-paced oscillations in retinoid receptor activity: evidence for a potential role for RIP140. PLoS One. 2009;4(10):e7639.CrossRefPubMedPubMedCentral
28.
Puri V, Virbasius JV, Guilherme A, Czech MP. RNAi screens reveal novel metabolic regulators: RIP140, MAP4k4 and the lipid droplet associated fat specific protein (FSP) 27. Acta Physiol (Oxf). 2008;192(1):103–15.CrossRef
29.
Morganstein DL, Christian M, Turner JJ, Parker MG, White R. Conditionally immortalized white preadipocytes: a novel adipocyte model. J Lipid Res. 2008;49(3):679–85.CrossRefPubMed
30.
Puri V, Chakladar A, Virbasius JV, et al. RNAi-based gene silencing in primary mouse and human adipose tissues. J Lipid Res. 2007;48(2):465–71.CrossRefPubMed
31.
Powelka AM, Seth A, Virbasius JV, et al. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes. J Clin Invest. 2006;116(1):125–36.CrossRefPubMed
32.
Xue J, Zhao H, Shang G, et al. RIP140 is associated with subclinical inflammation in type 2 diabetic patients. Exp Clin Endocrinol Diabetes. 2012;121(1):37–42.CrossRefPubMed
33.
Berriel Diaz M, Krones-Herzig A, Metzger D, et al. Nuclear receptor cofactor receptor interacting protein 140 controls hepatic triglyceride metabolism during wasting in mice. Hepatology. 2008;48(3):782–91.CrossRefPubMed
34.
Nautiyal J, Steel JH, Mane MR, et al. The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals. Development. 2012;140(5):1079–89.CrossRef
35.
Heim KC, White KA, Deng D, et al. Selective repression of retinoic acid target genes by RIP140 during induced tumor cell differentiation of pluripotent human embryonal carcinoma cells. Mol Cancer. 2007;6:57.CrossRefPubMedPubMedCentral
36.
Lapierre M, Bonnet S, Bascoul-Mollevi C, et al. RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis. J Clin Invest. 2012;124(5):1899–913.CrossRef
Metadata
Title
Downregulation of RIP140 in hepatocellular carcinoma promoted the growth and migration of the cancer cells
Authors
Dexiang Zhang
Yueqi Wang
Yuedi Dai
Jiwen Wang
Tao Suo
Hongtao Pan
Han Liu
Sheng Shen
Houbao Liu
Publication date
01-03-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2815-y

Other articles of this Issue 3/2015

Tumor Biology 3/2015 Go to the issue

Research Article

The polymorphism MMP1 −1607 (1G>2G) is associated with a significantly increased risk of cancers from a meta-analysis

Research Article

PX-12 induces apoptosis in Calu-6 cells in an oxidative stress-dependent manner

Research Article

RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway

Review

Biomarkers and signaling pathways of colorectal cancer stem cells

Research Article

Impact of MDM2 gene polymorphism on sarcoma risk

Research Article

RAB34 was a progression- and prognosis-associated biomarker in gliomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits